Floatz logo

Tuvusertib

Advanced Malignant Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

123 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2BB
Palbociclib
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Vinorelbine
OHSU Knight Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

Tuvusertib is also rated in:

prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →
prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
castration-resistant prostate carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →